| Project/Area Number |
18K16918
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Taoka Kazuki 東京大学, 医学部附属病院, 助教 (30529178)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 眼内悪性リンパ腫 / 遺伝子 / 眼内リンパ腫 / BTK阻害剤 / MYD88 |
|---|
| Outline of Final Research Achievements |
We have developed a cancer adjuvant diagnostic method using ctDNA in intraocular fluid of intraocular malignant lymphomas. We identified the causative genes of intraocular malignant lymphoma, and 94% (46/49 cases) of intraocular malignant lymphomas were covered by four main specific genes (MYD88, CD79B, X, Y). Although intraocular lymphoma specimens are very small samples, the method of simultaneous pre-amplification of four specific genes in the valve (patent pending) of minute ctDNA made it possible to detect four disease-specific genes (MYD88, CD79B, X, and Y). CD79B is particularly important for the treatment of intraocular lymphoma due to its high risk of central recurrence.
|
| Academic Significance and Societal Importance of the Research Achievements |
眼内悪性リンパ腫は、診断の困難さや、治療の標準化もいまだできていない難治性希少疾患である。研究代表者は、眼内悪性リンパ腫の疾患特異的遺伝子の解析を行い、同定した。さらに、予後不良遺伝子を特定した。また、疾患特異的遺伝子を標的とした医師主導試験を現在、開始している。今後、このような希少疾患においても、診断の標準化、治療薬の開発、治療法の標準化に尽力していきたい。
|
